Citi analyst Liav Abraham admits she's "somewhat confused" by the selloff in shares of Endo International following the company's Q3 results. The company posted a "solid beat-and-raise quarter," which was accompanied by "constructive commentary" by management on the fundamentals of both the business and the generics industry, Abraham tells investors in a research note. She continues to see upside to Street estimates, though acknowledges the lack of color provided on the earnings call regarding dynamics heading into 2019 "could have led to some frustration amongst investors." The analyst keeps a Buy rating on Endo with a $19 price target.